Article info

Original research
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Authors

  • Minoo Mohraz Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Mohammadreza Salehi Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Payam Tabarsi Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Mohsen Abbasi-Kangevari Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Seyyed-Hadi Ghamari Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Erfan Ghasemi Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Maryam Amini Pouya Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Negar Rezaei Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, IranEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Naser Ahmadi Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Kazem Heidari Clinical Trial Center (CTC), Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Mohammad-Reza Malekpour Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Mojtaba Nasiri Clinical Trial Center (CTC), Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Ali Akbar Amirzargar Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Sahar Saeedi Moghaddam Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Bagher Larijani Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  • Hamed Hosseini Clinical Trial Center (CTC), Tehran University of Medical Sciences, Tehran, IranCenter for Research & Training in Skin Diseases & Leprosy (CRTSDL), Tehran University of Medical Sciences, Tehran, Iran PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Hamed Hosseini; hmdhosseini{at}gmail.com
View Full Text

Citation

Mohraz M, Salehi M, Tabarsi P, et al
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Publication history

  • Received August 30, 2021
  • Accepted March 16, 2022
  • First published April 8, 2022.
Online issue publication 
April 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.